Literature DB >> 24856295

How steroids steer T cells.

Claude Libert1, Lien Dejager2.   

Abstract

Recent papers from Mahata et al. and Bereshchenko et al. reveal how steroids steer immune responses by tipping T helper (Th) subset balances and activities. Pregnenolone produced by Th2 cells mediates immunosuppressive responses, and glucocorticoids stimulate regulatory T cell development via the induction of GILZ expression.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24856295     DOI： 10.1016/j.celrep.2014.04.041

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  25 in total

1.  Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.

Authors:  Ammar Sukari; Misako Nagasaka; Roba Alhasan; Dhaval Patel; Antoinette Wozniak; Radhakrishnan Ramchandren; Ulka Vaishampayan; Amy Weise; Lawrence Flaherty; Hyejeong Jang; Seongho Kim; Shirish Gadgeel
Journal:  Anticancer Res       Date:  2019-02       Impact factor: 2.480

Review 2.  Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature.

Authors:  Fausto Meriggi; Alberto Zaniboni
Journal:  Cancer Immunol Immunother       Date:  2020-11-09       Impact factor: 6.968

3.  Commensal Propionibacterium strain UF1 mitigates intestinal inflammation via Th17 cell regulation.

Authors:  Natacha Colliou; Yong Ge; Bikash Sahay; Minghao Gong; Mojgan Zadeh; Jennifer L Owen; Josef Neu; William G Farmerie; Francis Alonzo; Ken Liu; Dean P Jones; Shuzhao Li; Mansour Mohamadzadeh
Journal:  J Clin Invest       Date:  2017-09-25       Impact factor: 14.808

4.  Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Authors:  Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza
Journal:  J Neurooncol       Date:  2019-03-07       Impact factor: 4.130

Review 5.  The immunopathobiology of T cells in stress condition: a review.

Authors:  Mostafa Khedri; Azam Samei; Mahdi Fasihi-Ramandi; Ramezan Ali Taheri
Journal:  Cell Stress Chaperones       Date:  2020-04-21       Impact factor: 3.667

Review 6.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 7.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

Review 8.  Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction.

Authors:  Vaia Florou; Sonam Puri; Ignacio Garrido-Laguna; Breelyn A Wilky
Journal:  Ann Transl Med       Date:  2021-06

9.  Metabolome modulation of the host adaptive immunity in human malaria.

Authors:  Wael Abdrabou; Mame Massar Dieng; Aïssatou Diawara; Samuel Sindié Sermé; Dareen Almojil; Salif Sombié; Noelie Bere Henry; Désiré Kargougou; Vinu Manikandan; Issiaka Soulama; Youssef Idaghdour
Journal:  Nat Metab       Date:  2021-06-10

10.  Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.

Authors:  Hiroki Ishihara; Yuki Nemoto; Kazutaka Nakamura; Takashi Ikeda; Hidekazu Tachibana; Hironori Fukuda; Kazuhiko Yoshida; Hirohito Kobayashi; Junpei Iizuka; Hiroaki Shimmura; Yasunobu Hashimoto; Toshio Takagi; Hideki Ishida; Tsunenori Kondo; Kazunari Tanabe
Journal:  Target Oncol       Date:  2021-06-26       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.